Rheumatology, Oxford Journals
By Oxford University Press
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
A podcast from Rheumatology that includes an in-depth interview with a research expert on an important topic of the day.
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
|
1 |
CleanPsoriatic arthritis and a placebo controlled RCT- (April 2012) | Methotrexate in psoriatic arthritis - does it really work or are we just giving a placebo? Listen to Professor Robert Moots and Dr Robert Thompson, University of Liverpool discuss the management psoriatic arthritis and analyse a major new randomized placebo-controlled trial of MTX in PsA article recently published by G Kingsley et al. Will this change your practice?To listen to the podcast, click below: Psoriatic arthritis and a placebo controlled RCTClick on the following link to read the related paper for free:A randomized placebo-controlled trial of MTX in PsA | 4/13/12 | Free | View In iTunes |
|
2 |
CleanBSR and BHPR guidelines on the use of rituximab – (Feb 2012) | How do you manage refractory rheumatoid arthritis? Listen to Professor Robert Moots, Editor, and Professor Paul Peter Tak from the University of Amsterdam, discuss advances in the treatment of RA and consider differences between clinical trials and real life clinical work. They also debate important new guidelines for the use of the rituximab in rheumatoid arthritis published in the Journal.What is your view on this? Listen to the Podcast, look up the paper and make up your own mind.To listen to the podcast click below:Use of rituximabClick on the following link to read the related paper for free:BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis | 3/21/12 | Free | View In iTunes |
|
3 |
CleanEarly Rheumatoid Arthritis treatment strategies - (June 2011) | Professor Robert Moots and Professor Janet Pope talk about treatment strategies for early rheumatoid arthritis and the influence cost-effectiveness has. To further highlight the issues they discuss a paper by Schipper et al. comparing the cost-effectiveness of 3 different treatment strategies for patients with early RA.To listen to the podcast click below: Treatment strategies Click on the following link to read the related paper for free: Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective | 6/23/11 | Free | View In iTunes |
|
4 |
CleanPatient perceptions - (June 2011) | Professor Robert Moots talks to Dr Fernando Cavalcanti about inflammatory arthritis and its treatment in Brazil, highlighting cultural differences in disease management and between patient and Doctor perceptions. They also discuss a review by Verschueren and Westhovens on the challenges of putting scientific treatment into clinical practice.To listen to the podcast click below: Patient perceptions Click on the following link to read the related paper for free:Optimal care for early RA patients: the challenge of translating scientific data into clinical practice | 6/23/11 | Free | View In iTunes |
|
5 |
CleanInflammatory myopathies - (June 2011) | Professor Robert Moots and Dr Piet van Riel discuss the treatment of inflammatory myopathies and their efficacies in patients. They talk about a paper, on which Dr van Riel is a co-author, investigating the use of rituximab to treat refractory inflammatory myopathies. They look into the reasons behind the study and give advice for people looking after patients with inflammatory myopathies.To listen to the podcast click below: Inflammatory myopathiesClick on the following link to read the related paper for free: Rituximab treatment in patients with refractory inflammatory myopathies | 6/23/11 | Free | View In iTunes |
|
6 |
CleanCohorts in rheumatoid arthritis - (May 2011) | Professor Robert Moots and Professor Nancy Lane discuss a paper by Liao et al. about a rheumatoid arthritis cohort in Boston, USA. They talk about the use and importance of such cohorts and how they can inform treatment strategies and practices. They look into the strengths, limitations and challenges for linking bed-side observations to laboratory developments.To listen to the podcast click below: Rheumatoid arthritis cohortsClick on the following link to read the related paper for free:Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study | 5/31/11 | Free | View In iTunes |
|
7 |
Clean50th Anniversary: A perspective on the past - (March 2011) | As part of the Journal’s 50th Anniversary celebrations Professor Robert Moots talks to Professor David GI Scott and Dr Michael Snaith about how the rheumatology field has changed over the past 60 years. They discuss treatment, therapeutic and practice developments and how a greater understanding of musculoskeletal disease has shaped these advancements.To listen to the podcast click below: A perspective on the pastTo find out more information regarding the Journal’s 50th celebrations please click here. | 4/4/11 | Free | View In iTunes |
|
8 |
CleanRegistries - (January 2011) | Professor Robert Moots and Professor David Isenberg discuss registries, what they are, their aims and outcomes. They highlight the British Society for Rheumatology Biologics Register, the largest biologics register in the world, detailing its design, aims and findings. Professor David Isenberg has been a guest Editor on the Journal’s themed issue on registries, a collection of papers on this topic.To listen to the podcast click below:RegistriesTo read the Journal’s themed issue on Registries in Rheumatological and Musculoskeletal Conditions please click here. | 1/20/11 | Free | View In iTunes |
|
9 |
CleanIs rheumatoid arthritis a genetically distinct subset? - (September 2010) | Is rheumatoid arthritis a single disease or a group of related diseases? Professor Robert Moots and Professor Anthony Russell discuss this issue, probing into a paper by Ohmura et al. published in Rheumatology. They discuss the key developments of this paper, what it means for treatment and its potential limitations.To listen to the podcast click below:Is rheumatoid arthritis a genetically distinct subset?Click on the following link to read the related paper for free:Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. | 11/16/10 | Free | View In iTunes |
|
10 |
CleanFactors predictive of thrombotic events in SLE patients - (August 2010) | The Editor Professor Robert Moots and Professor Mohammed Tikly, who is from the University of the Witwatersrand in South Africa, discuss a paper by Burgos et al. about the complications of thrombic events in systemic lupus and the implications of this for clinical practice.To listen to the podcast click below:Factors predictive of thrombotic events in SLE patientsClick on the following link to read the related paper for free:Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients. | 10/20/10 | Free | View In iTunes |
|
11 |
CleanSpondyloarthropathies: Ankylosing spondylitis with and without concomitant psoriasis - (July 2010) | In this podcast Professor Robert Moots and Dr Dirk Elewaut discuss spondyloarthropathy diseases and their manifestations. They then go on to discuss a paper by Bruan et al. recently published in Rheumatology on the clinical manifestations of ankylosing spondylitis with and without concomitant psoriasis. They discuss the key issues the paper investigates and the study’s limitations. | 8/4/10 | Free | View In iTunes |
|
12 |
CleanIncrease in ferritin levels and interstitial lung disease in dermatomyositis - (May 2010) | Can measurement of serum ferritin predict the development and severity of acute interstitial lung disease in dematomyositis? Professors Moots and Panayi delve into the paper by Gono et al who propose that the acute phase protein, ferritin, may represent a biomarker for complications in dermatomyositis. To listen to their discussion about this study, issues the paper addressed and its limitations, please click link below. | 5/12/10 | Free | View In iTunes |
|
13 |
CleanCost of using TNF-alpha inhibitors - (April 2010) | What is the cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis?. This paper, set in Finland, by Hallinen et al. is discussed by Professor Robert Moots and Dr. Ronald Frits van Vollenhoven. In the Podcast, they discuss current use of biologics, the effectiveness of TNF inhibitors, DMARDs and rituximab and consider whether the economic model used in this paper can effectively determine relative cost-effectiveness in a clinical setting. | 3/29/10 | Free | View In iTunes |
|
14 |
CleanCardiovascular disease and rheumatoid arthritis: what is the link? - (March 2010) | An MRI study about understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation by Puntmann et al. is the paper for the discussion between Professor Robert Moots and Dr Christopher Edwards. Is there a link between cardiovascular diseases and RA, how does this association affect patients with RA and questions about this study are answered in this podcast. | 3/16/10 | Free | View In iTunes |
|
15 |
CleanHypermobility in children - (February 2010) | A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility by Sue et al. published in Rheumatology is discussed by Robert Moots and Michael Beresford. What is childhood hypermobility and how does it present? Answers to these questions and discussions about the trial form the basis for this podcast. | 3/9/10 | Free | View In iTunes |
|
16 |
CleanThe role of biomarkers in the treatment of rheumatoid arthritis - (January 2010) | Robert Moots and Stephen Hall discuss the challenges in identifying biomarkers for selecting treatment and predicting adverse events in rheumatoid arthritis. They then discuss a paper by Quartuccio et al. investigating the utility of rheumatoid factor, anti-CCP antibodies and response to TNFi as potential predictors of response to rituximab in rheumatoid arthritis. | 1/25/10 | Free | View In iTunes |
|
17 |
CleanRheumatoid arthritis in elderly patients - (December 2009) | Is rheumatoid arthritis a homogeneous disease and can it be categorized by age? In our next podcast, Robert Moots with Daniel Solomon discusses not only these questions but also a study recently published by Rheumatology by Marcus Köller et al about the response of methotrexate or TNF inhibitors in elderly patients. | 12/14/09 | Free | View In iTunes |
|
18 |
CleanActive rheumatoid arthritis - (November 2009) | In this podcast, Robert Moots and Roy Fleischmann discuss aspects of rheumatoid arthritis and concerns that patients commonly have about the disease. They then discuss a paper published in the Journal by Aslam Anis et al. about the COMET study that examined the effect of etanercept on work productivity in patients with active rheumatoid arthritis. | 11/23/09 | Free | View In iTunes |
|
19 |
CleanManagement of Systemic Sclerosis - (July 2009) | Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therapy using rituximab - in an article recently published in Rheumatology. | 7/1/09 | Free | View In iTunes |
|
20 |
CleanAntiphospholipid antibody syndrome - (June 2009) | In this first Podcast from Rheumatology, Munther Khameshta (St Thomas' Hospital London) and Anisur Rahman (University College London) discuss aspects of treatment of APS today and the potential for future therapy, in the context of recent advances in understanding the pathological processes that underlie this disease. | 5/27/09 | Free | View In iTunes |
|
21 |
CleanANCA-associated vasculitis- (March 2012) | Professor Robert Moots and Dr Alfred Mahr discuss the challenges of ANCA-associated vasculitis, use of cyclophosphamide and granulomotosis with angiitis. They also discuss the use of rituximab particularly in light of the recommendations published by Guerry et al., how strong is the evidence base for these recommendations and how do these recommendations differ from Dr Mahr’s practice?To listen to the podcast, click below:ANCA-associated vasculitisClick on the following link to read the related paper for free: Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis | Free | View In iTunes |
| Total: 21 Episodes |
Listeners also subscribed to
- RWCS: Rheumatology Winter Clinical Symposium
- Rheumatology Winter Clinical Symposium
- View In iTunes
- Biologic Therapy In Rheumatoid Arthritis
- Rheumatology News International
- View In iTunes
- Peerview Rheumatology CME/CNE/CPE Video Podcast
- PVI, PeerView Institute for Medical Education
- View In iTunes
